QR-kod

CRAFITY score benefits hepatocellular carcinoma patients treated with transarterial chemoembolization and lenvatinib

Abstract Background The CRAFITY score serves as a simple and effective predictive model for individuals diagnosed with hepatocellular carcinoma (HCC) and subjected to treatment with atezolizumab and bevacizumab (Atez/Bev). However, no large sample size studies have reported the application of the CR...

Full beskrivning

Sparad:
Huvudupphov: Lin Zhang, Hongcai Yang, Shangkun Ning, Zhijuan Wu, Dianzhe Wang, Hexin Liang, Chunni Wang, Xu Chang
Materialtyp: Artigo
Språk:Inglês
Utgiven: Wiley 2024-06-01
Serie:Cancer Medicine
Ämnen:
alpha‐fetoprotein
CRAFITY score
C‐reactive protein
hepatocellular carcinoma
Lenvatinib
TACE
Länkar:https://doi.org/10.1002/cam4.7410
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk